Apyx Medical (NASDAQ:APYX – Get Rating) posted its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02), MarketWatch Earnings reports. Apyx Medical had a negative return on equity of 26.79% and a negative net margin of 31.27%. During the same period last year, the business posted ($0.14) EPS. Apyx Medical updated its FY 2022 guidance to EPS.
Apyx Medical stock opened at $3.65 on Friday. The business has a 50 day simple moving average of $5.76 and a 200-day simple moving average of $10.14. Apyx Medical has a 12 month low of $3.01 and a 12 month high of $17.50.
Several equities research analysts have recently weighed in on the company. Colliers Securities reissued a “buy” rating on shares of Apyx Medical in a research report on Tuesday, March 22nd. Zacks Investment Research lowered Apyx Medical from a “hold” rating to a “sell” rating in a report on Friday. Finally, Piper Sandler cut their target price on Apyx Medical from $12.00 to $6.00 in a research report on Thursday.
Apyx Medical Company Profile (Get Rating)
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.
- Get a free copy of the StockNews.com research report on Apyx Medical (APYX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.